About
Our Team
Board of Directors
Scientific Advisors
Collaborations
Programs
Programs and Pipeline
X-Linked Retinoschisis
Achromatopsia
X-Linked Retinitis Pigmentosa
Optogenetics
Age-Related Macular Degeneration
Science
Clinical Trials
Patients
Welcome Patients
About Enrollment
Patient Partners
Careers
Investors
Say Hello
Text size
A
A
About
Our Team
Board of Directors
Scientific Advisors
Collaborations
Programs
Programs and Pipeline
X-Linked Retinoschisis
Achromatopsia
X-Linked Retinitis Pigmentosa
Optogenetics
Age-Related Macular Degeneration
Science
Clinical Trials
Patients
Welcome Patients
About Enrollment
Patient Partners
Careers
Investors
Say Hello
Latest AGTC News
April 18, 2018
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
February 24, 2018
AGTC Announces Completion of Enrollment of Phase 1/2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
1
2
3
4
5
Visionary science for life changing cures.
Contact us
Join our team
×
Contact Us
I am a...
Patient
Caregiver
Healthcare Provider
Other
[recaptcha]
